Outset Medical, Inc. Q4 FY2024 earnings call

• The business performed well in Q4 with sequential revenue growth, increased gross margin, and reduced operating expenses. - Strong recurring revenue driven by over 6,000 Tablo's in installed base, with 13% sequential and 17% year-over-year growth. - Success in acute care providers with nearly 4,500 Tablo consoles in 850 acute and subacute sites. - FDA warning letter from July 2023 officially closed after comprehensive inspection. - Recapitalization in January with $172.7 million equity financing, reducing debt to $100 million. - National sales training meeting held to enhance sales team competency. - Priorities for 2025 include reigniting revenue growth, expanding gross margin, and accelerating path to profitability.

Fourth quarter revenue was $29.5 million, with full-year 2024 revenue of $113.7 million. Product revenue in Q4 was $21 million (consisting of console revenue $5.8 million and treatment revenue $15.3 million), and full-year product revenue was $81 million. Service and other revenue in Q4 was $8.5 million, with full-year $32.7 million. Recurring revenue in Q4 was $23.7 million, up 13% sequentially and 17% year-over-year, and full-year recurring revenue was $83.9 million, a 21% growth. Q4 gross margin was 37.6%, increasing 119 basis points sequentially and nearly 11 percentage points year-over-year. Full-year gross margin was 35.6%, and excluding manufacturing under absorption, it was over 40%.

• 2025 revenue expected to be between $115 million to $125 million, with midpoint implying 10% growth in installed base and recurring revenue. - Full-year gross margin expected in the high 30% range, with exclusion of manufacturing under absorption, gross margin exiting 2025 above 40% in Q4. - OpEx in 2025 projected to be roughly $90 million, with cash use in 2025 under $50 million, less than half of 2024's $103 million. - Tariffs proposed on goods from Mexico: no exposure as products covered under special exemption, with inventory in US and ability to shift production to Thailand if needed.

Q: Qualitative and quantitative outlook on console side.

A: Leslie Trigg discussed changes in sales force, pipeline growth (over 10% in Q4 2025 pipeline, 70% of top opportunities in latest sales stages), and diversification.

Q: What drove strong consumables revenue?

A: Nabeel Ahmed mentioned strong console utilization on larger installed base.

Q: Cadence for 2025 gross margins and OpEx.

A: Nabeel Ahmed said gross margin expected to expand in high 30% zone, affected by product mix; OpEx expected to be $90 million, relatively linear.

Q: Tieing cash outlay reduction and capital intensity.

A: Nabeel Ahmed explained cash guidance due to revenue growth, gross margin expansion, OpEx reduction, inventory and console build plan changes, and debt reduction leading to lower interest expense.